help button home button Am J Pathol ASIP 2008 Summer Academy, Molecular Methcanisms of Human Disease: Injury, Inflammation, and Tissue Repair
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ruizeveld de Winter, J. A.
Right arrow Articles by van der Kwast, T. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruizeveld de Winter, J. A.
Right arrow Articles by van der Kwast, T. H.

American Journal of Pathology, Vol 144, 735-746, Copyright © 1994 by American Society for Investigative Pathology

REGULAR ARTICLES

Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer

JA Ruizeveld de Winter, PJ Janssen, HM Sleddens, MC Verleun-Mooijman, J Trapman, AO Brinkmann, AB Santerse, FH Schroder and TH van der Kwast
Department of Pathology, Erasmus University, Rotterdam, The Netherlands.

Heterogeneity in human androgen receptor (hAR) expression in prostate cancer is considered to be implicated in tumor progression. hAR expression was therefore studied immunohistochemically in localized and locally progressive, hormone refractory (HR) prostate cancer. Because altered functional activity of the hAR may be due to changes in the structural integrity of the hAR gene, exons 2 to 8 of the hAR gene were assessed for mutations by single-strand conformation polymorphism (SSCP) analysis and exon 1 was analyzed for the size of the CAG repeat. The hormone binding capacity, a prerequisite for ligand-regulated receptor function, was determined by a ligand binding assay. Coexpression of the hAR and prostate-specific antigen (PSA) was studied by a sequential double immunoenzymatic staining to verify whether PSA expression is a parameter of hAR function. Almost all human prostatic carcinomas revealed heterogeneous hAR expression, regardless of tumor differentiation and progression. Putative predominance of hAR-negative tumor areas in HR prostate cancer was not observed. No hAR gene mutations or major changes in the CAG repeat were found in the 18 HR carcinomas or in the 9 control samples. Moreover, all selected hAR- expressing cancers were able to bind the synthetic androgen methyltrienolone (R1881). Immunoenzymatic double staining revealed even PSA expression in hAR-negative tumor areas. PSA immunohistochemistry in human prostatic carcinomas therefore is of no use in determining hAR functional activity. Thus, most prostatic carcinomas, even when progressed to a state of hormone insensitivity, contain a structurally intact hAR gene, heterogeneously expressed with retained androgen binding capacity.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
Y. Tang, L. Wang, O. Goloubeva, M. Afnan Khan, B. Zhang, and A. Hussain
Divergent Effects of Castration on Prostate Cancer in TRAMP Mice: Possible Implications for Therapy
Clin. Cancer Res., May 15, 2008; 14(10): 2936 - 2943.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. H. Suh, E.-Y. Gong, J. B. Kim, I.-K. Lee, H.-S. Choi, and K. Lee
Sterol Regulatory Element-Binding Protein-1c Represses the Transactivation of Androgen Receptor and Androgen-Dependent Growth of Prostatic Cells
Mol. Cancer Res., February 1, 2008; 6(2): 314 - 324.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. H. Suh, M. Shong, H.-S. Choi, and K. Lee
CR6-Interacting Factor 1 Represses the Transactivation of Androgen Receptor by Direct Interaction
Mol. Endocrinol., January 1, 2008; 22(1): 33 - 46.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Schayowitz, G. Sabnis, V. C.O. Njar, and A. M.H. Brodie
Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro
Mol. Cancer Ther., January 1, 2008; 7(1): 121 - 132.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
T.-H. Li, H. Zhao, Y. Peng, J. Beliakoff, J. D. Brooks, and Z. Sun
A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells
Nucleic Acids Res., April 10, 2007; (2007) gkm198v1.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. G. Hermans, R. van Marion, H. van Dekken, G. Jenster, W. M. van Weerden, and J. Trapman
TMPRSS2:ERG Fusion by Translocation or Interstitial Deletion Is Highly Relevant in Androgen-Dependent Prostate Cancer, But Is Bypassed in Late-Stage Androgen Receptor-Negative Prostate Cancer.
Cancer Res., November 15, 2006; 66(22): 10658 - 10663.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
Z. Dong, Y. Liu, S. Lu, A. Wang, K. Lee, L.-H. Wang, M. Revelo, and S. Lu
Vav3 Oncogene Is Overexpressed and Regulates Cell Growth and Androgen Receptor Activity in Human Prostate Cancer
Mol. Endocrinol., October 1, 2006; 20(10): 2315 - 2325.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. S. Bhattacharyya, A. V. Krishnan, S. Swami, and D. Feldman
Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
Mol. Cancer Ther., June 1, 2006; 5(6): 1539 - 1549.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. M. Hillier, J. C. Marquis, B. Zayas, J. S. Wishnok, R. G. Liberman, P. L. Skipper, S. R. Tannenbaum, J. M. Essigmann, and R. G. Croy
DNA adducts formed by a novel antitumor agent 11{beta}-dichloro in vitro and in vivo.
Mol. Cancer Ther., April 1, 2006; 5(4): 977 - 984.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
Z. Salah, M. Maoz, I. Cohen, G. Pizov, D. Pode, M. S. Runge, and R. Bar-Shavit
Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression
FASEB J, January 1, 2005; 19(1): 62 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Verras, J. Brown, X. Li, R. Nusse, and Z. Sun
Wnt3a Growth Factor Induces Androgen Receptor-Mediated Transcription and Enhances Cell Growth in Human Prostate Cancer Cells
Cancer Res., December 15, 2004; 64(24): 8860 - 8866.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. A. Heinlein and C. Chang
Androgen Receptor in Prostate Cancer
Endocr. Rev., April 1, 2004; 25(2): 276 - 308.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. L. Mohler, C. W. Gregory, O. H. Ford III, D. Kim, C. M. Weaver, P. Petrusz, E. M. Wilson, and F. S. French
The Androgen Axis in Recurrent Prostate Cancer
Clin. Cancer Res., January 15, 2004; 10(2): 440 - 448.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. K. Habib, M. Ross, C. W. Bayne, P. Bollina, K. Grigor, and K. Chapman
The Loss of 5{alpha}-Reductase Type I and Type II mRNA Expression in Metastatic Prostate Cancer to Bone and Lymph Node Metastasis
Clin. Cancer Res., May 1, 2003; 9(5): 1815 - 1819.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
D. J. Lamb, E. Puxeddu, N. Malik, D. L. Stenoien, R. Nigam, G. Y. Saleh, M. Mancini, N. L. Weigel, and M. Marcelli
Molecular Analysis of the Androgen Receptor in Ten Prostate Cancer Specimens Obtained Before and After Androgen Ablation
J Androl, March 1, 2003; 24(2): 215 - 225.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Calvo, N. Xiao, J. Kang, C. J. M. Best, I. Leiva, M. R. Emmert-Buck, C. Jorcyk, and J. E. Green
Alterations in Gene Expression Profiles during Prostate Cancer Progression: Functional Correlations to Tumorigenicity and Down-Regulation of Selenoprotein-P in Mouse and Human Tumors
Cancer Res., September 15, 2002; 62(18): 5325 - 5335.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X.-B. Shi, A.-H. Ma, L. Xia, H.-J. Kung, and R. W. de Vere White
Functional Analysis of 44 Mutant Androgen Receptors from Human Prostate Cancer
Cancer Res., March 1, 2002; 62(5): 1496 - 1502.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
F. Andriani, B. Nan, J. Yu, X. Li, N. L. Weigel, M. J. McPhaul, S. Kasper, S. Kagawa, B. Fang, R. J. Matusik, et al.
Use of the Probasin Promoter ARR2PB to Express Bax in Androgen Receptor-Positive Prostate Cancer Cells
J Natl Cancer Inst, September 5, 2001; 93(17): 1314 - 1324.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. E. Taplin and S.-M. Ho
The Endocrinology of Prostate Cancer
J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3467 - 3477.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
I. Leav, K.-M. Lau, J. Y. Adams, J. E. McNeal, M.-E. Taplin, J. Wang, H. Singh, and S.-M. Ho
Comparative Studies of the Estrogen Receptors {beta} and {{alpha}} and the Androgen Receptor in Normal Human Prostate Glands, Dysplasia, and in Primary and Metastatic Carcinoma
Am. J. Pathol., July 1, 2001; 159(1): 79 - 92.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. J. Linja, K. J. Savinainen, O. R. Saramäki, T. L. J. Tammela, R. L. Vessella, and T. Visakorpi
Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer
Cancer Res., May 1, 2001; 61(9): 3550 - 3555.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
S. M. Henshall, D. I. Quinn, C. S. Lee, D. R. Head, D. Golovsky, P. C. Brenner, W. Delprado, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland
Altered Expression of Androgen Receptor in the Malignant Epithelium and Adjacent Stroma Is Associated with Early Relapse in Prostate Cancer
Cancer Res., January 1, 2001; 61(2): 423 - 427.
[Abstract] [Full Text]

Home page
 Genes Dev.Home page
C. Abate-Shen and M. M. Shen
Molecular genetics of prostate cancer
Genes & Dev., October 1, 2000; 14(19): 2410 - 2434.
[Full Text]

Home page
 Cancer Res.Home page
M. Marcelli, M. Ittmann, S. Mariani, R. Sutherland, R. Nigam, L. Murthy, Y. Zhao, D. DiConcini, E. Puxeddu, A. Esen, et al.
Androgen Receptor Mutations in Prostate Cancer
Cancer Res., February 1, 2000; 60(4): 944 - 949.
[Abstract] [Full Text]

Home page
 Mol. Endocrinol.Home page
L. V. Nazareth, D. L. Stenoien, W. E. Bingman III, A. J. James, C. Wu, Y. Zhang, D. P. Edwards, M. Mancini, M. Marcelli, D. J. Lamb, et al.
A C619Y Mutation in the Human Androgen Receptor Causes Inactivation and Mislocalization of the Receptor with Concomitant Sequestration of SRC-1 (Steroid Receptor Coactivator 1)
Mol. Endocrinol., December 1, 1999; 13(12): 2065 - 2075.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
P. A. Koivisto, J. Schleutker, H. Helin, C. E.-v. Eekelen, O.-P. Kallioniemi, and J. Trapman
Androgen Receptor Gene Alterations and Chromosomal Gains and Losses in Prostate Carcinomas Appearing During Finasteride Treatment for Benign Prostatic Hyperplasia
Clin. Cancer Res., November 1, 1999; 5(11): 3578 - 3582.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. H. Xing and S. A. Rabbani
Regulation of Urokinase Production by Androgens in Human Prostate Cancer Cells: Effect on Tumor Growth and Metastases in Vivo
Endocrinology, September 1, 1999; 140(9): 4056 - 4064.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
C. W. Gregory, D. Kim, P. Ye, A. J. D’Ercole, T. G. Pretlow, J. L. Mohler, and F. S. French
Androgen Receptor Up-Regulates Insulin-Like Growth Factor Binding Protein-5 (IGFBP-5) Expression in a Human Prostate Cancer Xenograft
Endocrinology, May 1, 1999; 140(5): 2372 - 2381.
[Abstract] [Full Text]

Home page
 Am. J. Pathol.Home page
A. P. Stubbs, P. D. Abel, M. Golding, G. Bhangal, Q. Wang, J. Waxman, G. W.H. Stamp, and E.-N. Lalani
Differentially Expressed Genes in Hormone Refractory Prostate Cancer : Association with Chromosomal Regions Involved with Genetic Aberrations
Am. J. Pathol., May 1, 1999; 154(5): 1335 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. O. Olapade-Olaopa, E. H. MacKay, N. A. Taub, D. P. S. Sandhu, T. R. Terry, and F. K. Habib
Malignant Transformation of Human Prostatic Epithelium Is Associated with the Loss of Androgen Receptor Immunoreactivity in the Surrounding Stroma
Clin. Cancer Res., March 1, 1999; 5(3): 569 - 576.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken
Molecular Genetics and Epidemiology of Prostate Carcinoma
Endocr. Rev., February 1, 1999; 20(1): 22 - 45.
[Abstract] [Full Text]

Home page
 Endocr. Rev.Home page
C. Lopez-Otin and E. P. Diamandis
Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical Features
Endocr. Rev., August 1, 1998; 19(4): 365 - 396.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. M. Kokontis, N. Hay, and S. Liao
Progression of LNCaP Prostate Tumor Cells during Androgen Deprivation: Hormone-Independent Growth, Repression of Proliferation by Androgen, and Role for p27Kip1 in Androgen-Induced Cell Cycle Arrest
Mol. Endocrinol., July 1, 1998; 12(7): 941 - 953.
[Abstract] [Full Text]

Home page
 NEJMHome page
M.-E. Taplin, G. J. Bubley, T. D. Shuster, M. E. Frantz, A. E. Spooner, G. K. Ogata, H. N. Keer, and S. P. Balk
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
N. Engl. J. Med., May 25, 1995; 332(21): 1393 - 1398.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Cariou, J. C. H. Donovan, W. M. Flanagan, A. Milic, N. Bhattacharya, and J. M. Slingerland
Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells
PNAS, August 1, 2000; 97(16): 9042 - 9046.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American Society for Investigative Pathology.